

Meta Health Limited
(Incorporated in the Republic of Singapore)
(Company Registration No. 198804700N)

**ACQUISITION OF 55% OF THE ENTIRE ISSUED AND PAID-UP SHARE CAPITAL OF JAS
MEDICAL SCREENING CENTRE PTE LTD**

- RECEIPT OF LISTING AND QUOTATION NOTICE

1. INTRODUCTION

- 1.1. The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”) refers to the Company’s announcements dated 10 October 2024, 18 November 2024 and 28 November 2024 (the “**Previous Announcements**”) pertaining to the Company’s acquisition of 55,000 ordinary shares in the share capital of Jas Medical Screening Centre Pte Ltd (the “**Clinic**”), which represent 55% of the entire issued and paid-up share capital thereof, from Mr Lian Ah Lek (the “**Vendor**”) (the “**Transaction**”).
- 1.2. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Previous Announcements.

2. RECEIPT OF LISTING AND QUOTATION NOTICE

- 2.1. The Board wishes to announce that the Company has on 10 December 2024 received the listing and quotation notice from the SGX-ST for the dealing in, listing of and quotation for up to 41,640,400 Meta Shares, being the aggregate of (i) 23,331,000 Consideration Shares and up to 15,554,000 Earn-Out Shares to be issued to the Vendor, and (ii) up to 2,755,400 Introducer Shares to be issued to the Introducer, on the Catalist board of the SGX-ST (the “**LQN**”). Please refer to the Previous Announcements for the details relating to the allotment and issuance of the Consideration Shares and the Earn-Out Shares to the Vendor, and the Introducer Shares to the Introducer pursuant to the SPA and the Introducer Agreement respectively.
- 2.2. The LQN is subject to the Company’s compliance with the SGX-ST’s listing requirements.
- 2.3. The LQN is not to be taken as an indication of the merits of the Consideration Shares, the Earn-Out Shares, the Introducer Shares, the Transaction, the Company, its subsidiaries and their securities.

3. CAUTIONARY STATEMENT

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. As at the date of this announcement, there is no certainty or assurance that the Earn-Out Shares or the Contingent Introducer Shares will be allotted and issued, as they are subject to conditions which may or may not be fulfilled. Shareholders and potential investors of the Company are advised to read this announcement, the Previous Announcements and any further announcements by the Company carefully, and consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board

Gwendolin Lee Soo Fern
Company Secretary
11 December 2024

This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "Sponsor").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Zheng, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.